Article
Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
Applied immunohistochemistry & molecular morphology : AIMM - 1 Jun 2003
Colomer Anna, Erill Nadina, Verdú Montse, Roman Ruth, Vidal August, Cordon-Cardo Carlos, Puig Xavier
Abstract excerpt
Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to the analysis of p53. We have studied a series of 100 primary colorectal adenocarcinomas by immunohistochemistry with the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.